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Abstract
Background: Tyrosine kinase inhibitors (TKI) have enriched the therapeutic options in patients with renal cell
carcinoma (RCC), which frequently induce morphological changes in tumors. However, only little is known about
the biological activity of TKI. Circulating endothelial cells (CEC) have been associated with endothelial damage and,
hence, may serve as a putative marker for the biological activity of TKI. The main objective of our study was to
evaluate the predictive value of CEC, monocytes, and soluble vascular endothelial growth factor receptor (sVEGFR)-
2 in RCC patients receiving sunitinib treatment.
Methods: Analyses of CEC, monocytes, and sVEGFR-2 were accomplished for twenty-six consecutive patients with
metastatic RCC who received treatment with sunitinib (50 mg, 4 wks on 2 wks off schedule) at our institution in
2005 and 2006.
Results: In RCC patients CEC are elevated to 49 ± 44/ml (control 8 ± 8/ml; P = 0.0001). Treatment with sunitinib is
associated with an increase in CEC within 28 days of treatment in patients with a Progression free survival (PFS)
above the median to 111 ± 61 (P = 0.0109), whereas changes in patients with a PFS below the median remain
insignificant 69 ± 61/ml (P = 0.1848). Monocytes and sVEGFR2 are frequently altered upon sunitinib treatment, but
fail to correlate with clinical response, defined by PFS above or below the median.
Conclusions: Sunitinib treatment is associated with an early increase of CEC in responding patients, suggesting
superior endothelial cell damage in these patients as a putative predictive biomarker.
Background
Tyrosine kinase inhibitors (TKI) were recently success-
fully added to the armentarium to treat renal cell carci-
noma (RCC). Sunitinib, a first generation TKI which
targets VEGFR1-3, PDGFR a/ß, KIT, RET, CSF 1R and
FLT-3, has recently been approved for the treatment of
RCC [1]. Its antitumor activity is at least partially
mediated through inhibition of tumor vessel formation,
which can be demonstrated through sophisticated ima-
ging techniques, such as dynamic contrast enhanced
MRI. As these techniques are not commonly available
to most physicians, biomarkers which predict biological
and antitumor activity are desperately needed to ade-
quately monitor tumor therapy and predict tumor
response to sunitinib.
In RCC, inhibition of vessel formation is thought to be
the prime mechanism to achieve antitumor activity [2].
The biological relevance of the different VEGFR family
members in this process was elucidated in murine
models, and VEGFR-2 was determined to be the main
regulator of neo-angiogenesis and the most promising
target for therapeutic intervention [3]. Various activating
ligands were identified, which may bind with a distinct
affinity to VEGFR family members. Inhibition of these
targets correlated with significant changes of circulating
proteins and the application of sunitinib was associated
with changes of circulating VEGF, placental growth fac-
tor (PlGF) and sVEGFR-2 [4-6]. So far, such changes
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were associated with target inhibition in vivo but failed
to predict tumor response in patients [4,7].
Other markers, such as circulating endothelial cells
(CEC), have been studied in order to define the biologi-
cal response to these agents. Increased CEC levels were
demonstrated to correlate with vascular damage and are
observed in a variety of vascular disorders [8-11]. CEC
were thought to be shed from the endothelium and suc-
cessfully predict the activity of vessel damage seen in
vasculitis [11]. In cancer patients, elevated CEC levels
were also detected [12] and apoptotic CEC were recently
proposed to predict clinical outcome of metronomic
therapy in breast cancer patients [13]. In addition, the
predictive value of soluble markers was studied in treat-
ments with angiogenesis inhibitors. Soluble VEGFR-2
levels were reported to decrease during sunitinib treat-
ment but were not predictive for response in RCC and
GIST patients [4,5].
In this pilot study, we investigated the role of CEC
and sVEGFR2 as potential biomarkers in metastatic
RCC patients who were treated with sunitinib. Blood
samples were collected prior to and during the course
of sunitinib therapy and tumor response was monitored
according to RECIST criteria. Biomarkers were analyzed
for responding and non-responding patients either for
kinetic changes during the course of treatment or as a
single predictive marker prior to drug-exposure.
Methods
Patients
The study was conducted in accordance with the
Declaration of Helsinki and the local Institutional Review
Board approved the study protocol. Informed consent
was obtained prior to blood collections. 26 patients with
metastatic RCC were included in the analyses (Table 1).
Best response to therapy was defined as either stable
disease (SD) or objective response (OR) according to
RECIST criteria, and was determined by CT-scans at
baseline and every other cycle. Due to limited sample
size, responders were defined by either SD or OR, and
patients with progressive disease (PD) were deemed
non-responders. A total of 6 non-responders and 20
responders were identified within the study population.
No patient received treatment with a VEGFR-inhibitor
prior to sunitinib. 15 male and 11 female patients
entered the study with a mean age of 62 years (range
45-80). 18 patients had received at least one prior regi-
men and 8 patients were treatment naïve. Blood samples
from 20 healthy volunteers with a mean age of 59 (range
45-77) served as normal controls.
Study design
Blood samples for analyses of CEC, monocytes and
sVEGFR2 were collected in parallel in patients who
received treatment with sunitinib (50 mg OD 4 weeks
on - 2 weeks off) for metastatic RCC as standard of care
treatment prior to start of treatment, at day 14, day 28
and with the last dose of sunitinib of each subsequent
course for the duration of sunitinib therapy. Monocytes
were detected according to institutional standard on day
1, 14 and 28 during the first cycle and day 1 and/or 28
during subsequent cycles by complete blood counts.
The study was performed without external financial
support.
Preparation of blood samples
Blood samples were collected from 26 patients. Avail-
able probes at baseline consisted of 26 for CEC, 26 for
monocytes and 18 for sVEGFR2 analyses. After 14 days
of treatment, 17 probes were assessed for CEC, 23 for
monocytes and 14 for sVEGFR2. After 28 days, a total
of 23 probes were analyzed for CEC, 22 for monocytes
and 17 for sVEGFR2.
Blood samples for CEC analyses were taken and ana-
lyzed as previously described [14]. In brief, samples were
analyzed within 4 hours of non-traumatic venous punc-
ture in 7.5 ml ethylene-diamine tetra-acetic acid and
stored at 4°C if readout was not performed immediately.
Anti-CD 146-coated M-450 Dynabeads (Dynal, Norway)
were prepared as described by the manufacturer. 1 ml
blood was mixed with 1 ml buffer (phosphate-buffered
saline, 0.1% bovine serum albumin, 0.1% sodium azide,
and 0.6% sodium citrate) on ice, supplemented by 20 μl
of FcR-blocking agent (Miltenyi, Bergisch Gladbach,
Germany) and 50 μl anti-CD 146-coated Dynabeads (10
μg ml-1). Samples were mixed (30 min.) and rinsed with
Table 1 Patients’ Characteristics









clear cell 21 80
Age (range) 62 (45-80) years
Male 15
Female 11
Median PFS in days (range) 249 (63-953)
Best response
Objective response (OR) 11 42
Stable disease (SD) 9 35
Progressive disease (PD) 6 23
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buffer inside the magnet at 4°C and stained with FITC-
coupled Ulex europaeus lectin-1 solution (UEA-1,
Sigma-Aldrich, St. Louis, USA) for 1 hour in darkness.
CEC were then washed and visualized by fluorescence
microscopy at 553 nm, and counted employing a
Nageotte chamber. Serum for sVEGFR2 was immedi-
ately stored at -20°C and analyzed by ELISA-tests
according to manufacturer’s description (R&D Systems,
Minneapolis, USA).
Statistical analyses
Paired and unpaired Student’s t-Test were employed for
statistical analyses. Paired Student’s t-Test has been
utilized in groups with repeated measurements all other
t-test evaluations consisted of unpaired t-Tests. Kaplan-
Meier estimates were used to plot median progression
free survival (PFS). Descriptive statistics are utilized to
show the fraction of patients with distinct variables. Stan-
dard deviation is reported, if not otherwise specified.
Results
Patients with metastatic RCC exhibit higher CEC baseline
levels than normal controls
A total of 26 patients with metastatic RCC were included
in our study. Patients’ characteristics are depicted in table
1. In order to evaluate the role of CEC in RCC, we first
evaluated values in normal controls and untreated RCC
patients. Mean CEC values in metastatic RCC patients
were significantly higher than those from normal controls
(49 ± 44 CEC/ml vs. 8 ± 8 CEC/ml; P = 0.0001) (Figure 1).
Treatment with sunitinib is associated with an increase of
CEC as an early biological response
Sunitinib achieved a median PFS of 249 days (Figure 2),
which was associated with response to therapy (OR and
SD) in 77% of the patients. Clear cell histology (N = 21)
was the predominant tumor type and response to ther-
apy was noted in 17 patients (81%) and median PFS was
254 days. This subgroup of patients achieved baseline
CEC counts of 47 ± 43/ml. However, a distinct subtype
was noted in 5 patients (sarcomatoid N = 2; papillary
N = 2; chromophobe N = 1) and treatment with suniti-
nib resulted in tumor response (OR or SD) in 3 patients
(60%) and was associated with a median PFS of 156
days. A similar CEC count of 47 ± 46/ml was detected
in these patients at baseline (P = 0.9737).
We investigated the kinetics of CEC in patients trea-
ted with sunitinib, which is administered over 28 days
followed by a 14 day drug holiday. Probes were sampled
at baseline, days 14 and 28 during course one and on
the last day of drug administration of each course to
ensure maximum target inhibition for biological effects.
The analyses of all treated patients revealed significant
changes after 14 and 28 days of sunitinib treatment.
During the first course, mean values increased from 49
± 44 CEC/ml at baseline to 84 ± 59 CEC/ml after 14
days (P = 0.0331) and 89 ± 63 CEC/ml after 28 days (P
= 0.0159) of treatment. CEC declined during the subse-
quent treatment to baseline levels and below (range
19-58 CEC/ml). The course of CEC during sunitinib
treatment is depicted in a subset of patients (N = 13)
for whom repeated measures were available for the
duration of 238 days (Figure 3A).
To further define whether early CEC increase has a
predictive value for sunitinib treatment, we explored
CEC changes in subgroups of patients with a PFS above
or below the median PFS. An increased number of CEC
is thought to be associated with vascular damage, which
we considered a favorable early biological response to
sunitinib. We therefore analyzed CEC values during the
first course of treatment.
Increased CEC numbers were observed in patients
who had a PFS above the median. In these patients,
Figure 1 Levels of CEC are elevated in metastatic RCC patients.
Baseline levels of CEC in metastatic RCC patients were significantly
elevated compared to normal controls (CTR) (P = 0.0001). Mean
values for CEC were 8 ± 8 and 49 ± 44/ml in CTR and RCC patients,
respectively.
Figure 2 Progression free survival of sunitinib treatment. The
median progression free survival (PFS) with sunitinib is shown by
Kaplan-Meier estimate (median 249 days).
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mean CEC values increased from 40 ± 41 CEC/ml at
baseline to 111 ± 61 CEC/ml at day 28 (P = 0.0109)
(Figure 3B). In addition, early assessment at day 14 was
performed in 13 patients and showed a similar increase
in mean values to 93 ± 63 CEC/ml (P = 0.0067). In con-
trast, patients who achieved a median PFS below
the median exhibited no significant alteration of CEC
(53 ± 45 CEC/ml at baseline, 69 ± 61 CEC/ml at day 28;
P = 0.1848), supporting the notion that CEC increase
may represent a valuable marker for clinical activity
(Figure 3B). Early assessment at day 14 was available in
5 patients only. However, in these patients early assess-
ment was associated with an insignificant increase of
mean CEC values to 83 ± 30 CEC/ml (P = 0.3659).
While, baseline values of CEC prior to drug exposure
showed a trend to lower values (40 ± 41 CEC/ml) in
patients with a PFS above the median when compared
to patients with a PFS below the median (53 ± 45 CEC/
ml), these differences remained insignificant (P =
0.4414) and do not explain treatment outcome as a sin-
gle pre-dose evaluation.
Monocyte counts change in response to sunitinib
VEGFR-1 promotes vessel growth through recruitment
of monocytic blood cells [15], including endothelial pro-
genitor cells (EPC). Monocytes express VEGFR-1 [16]
and hence may represent a convenient surrogate marker
to measure sunitinib’s biological activity. Sunitinib treat-
ment resulted in significant decrease of mean monocyte
values from 594 ± 192/μl prior to treatment to 312 ±
136/μl and 278 ± 122/μl at 14 and 28 days of treatment,
respectively (Figure 4A). Washout of sunitinib after the
first and second treatment course was associated with
an increase of monocytes to baseline levels of 501 ±
178/μl and 467 ± 186/μl, respectively, indicating reversi-
ble target inhibition. Monocyte response was sustained
upon repeated challenge with sunitinib for 28 days (265
± 108/μl).
All patients showed a similar decline of monocyte
counts, irrespective of the duration of PFS to sunitinib.
Both groups showed a significant decrease of monocytes
on day 28 [P = 0.0006 (below median); P < 0.0001
(above median)]. However, monocyte values at day
14 and 28 were similar in both groups (P = 0.2070,
P = 0.3006, respectively) (Figure 4B).
Treatment with sunitinib is associated with decreased
sVEGFR2, but its kinetic change fails to predict clinical
response
sVEGFR2 was investigated as a potential predictive bio-
marker for response to sunitinib treatment. The mean
sVEGFR2 concentration prior to treatment was 13317 ±
3017 pg/ml. Sunitinib induced a 39% reduction of
sVEGFR2 (to 8180 ± 2301 pg/ml; P < 0.0001), which
remained repressed throughout further treatment. The
pattern of sVEGFR2 response is illustrated in Figure 5A
in patients with repeated measurement available for 70
days only. In these patients, sVEGFR2 dropped signifi-
cantly at day 28 (P < 0.0001) compared to baseline.
We then investigated subgroups of patients according
to their PFS to sunitinib, which was either above or
below the median. Mean sVEGFR2 levels prior to treat-
ment with sunitinib showed a trend for decreased counts
in patients with a PFS above the median (11724 ± 2278
pg/ml) compared to patients with a PFS below the med-
ian (14615 ± 4068 pg/ml), however, the difference
remained insignificant (P = 0.0814). Both groups showed
similar decrease of sVEGFR2 during the latter course of
treatment (day 28: 7157 ± 1800 pg/ml and 8484 ± 3737
pg/ml, respectively; P = 0.3760) (Figure 5B).
Figure 3 CEC display a characteristic response to treatment
with sunitinib. A) Characteristic changes of CEC counts are
depicted in 13 patients with repeated measures for the duration of
238 days. Curve shows a marked increase within 28 days, followed
by decreased CEC counts to a basal level. Bars show mean standard
error mean. B) Patients were grouped according to their PFS above
or below the median. CEC measured at baseline and after 28 days
of treatment with sunitinib are depicted for both groups. In patients
with PFS above the median mean CEC values increased significantly
from baseline 40 ± 41 CEC/ml to 111 ± 61 (P = 0.0109) at day 28.
However, in patients with PFS below the median, the increase from
53 ± 45 to 69 ± 61 CEC/ml remained insignificant (P = 0.1848).
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Discussion
Targeted agents have recently enriched the treatment of
renal cell carcinoma. Objective responses are frequently
seen in patients receiving targeted agents and approach
40% for patients treated with sunitinib [1]. However,
best objective responses often occur rather late during
the course of treatment with VEGFR-inhibitors. Axiti-
nib, a potent inhibitor of VEGFR, showed an objective
response in 44% of RCC patients [17], which were regis-
tered after 90-403 days of continuous treatment. Two
complete responses were detected at days 256 and 362,
respectively. Clearly, there is a need to identify biological
markers, which allow earlier prediction of tumor
response to anti-angiogenesis agents. Numerous markers
were recognized to be altered through sunitinib
treatment, including VEGFR ligands, soluble receptors
and endothelial cells [4-6]. Our work focused on CEC,
monocytes and sVEGFR2 in order to elucidate their role
as potential predictive markers in RCC patients treated
with sunitinib.
Patients with detectable tumors are known to have
increased levels of CEC as a consequence of endothelial
perturbation, but the implication of this observation for
prognosis or tumor response remains unclear [18-20].
Beerepoot et al. reported similar CEC values for healthy
controls and patients with SD as best tumor response,
whereas patients seemed to have elevated CEC at time
of progression [12]. Mancuso et al. reported normal
Figure 4 Treatment with sunitinib decreases circulating
monocytes in all treated patients, irrespective of their clinical
response to treatment. A) Monocytes decrease during repeated
exposure to sunitinib. However, increased values are measured after
the 2-weeks washout interval of sunitinib. B) Patients were grouped
according to PFS above or below the median. In both groups,
monocyte counts decrease significantly from baseline to day 28 [P
= 0.0006 (below median); P < 0.0001 (above median)]. However,
monocyte counts at day 1 and 28 remained similar between both
groups [P = 0.5701 (day 1), P = 0.3006 (day 28), respectively].
Figure 5 sVEGFR2 is a sensitive biomarker for sunitinib
treatment but fails to predict clinical response. A) In 16 patients,
repeated sVEGFR2 measurements were performed on days 1 - 70.
sVEGFR2 declines significantly during treatment with sunitinib (day
28: P < 0.0001). B) Patients were grouped according to PFS above
or below the median. Compared to baseline, sVEGFR2 decreased in
each group significantly on day 28 [P < 0.0001 (below median), P =
0.0048 (above median), respectively]. However, no difference was
shown at day 28 between both groups (P = 3760).
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levels of CEC in patients with complete remission of
lymphoma [19]. Patients in these studies received con-
ventional chemotherapeutics, which target the tumor
rather than its vasculature. Hence, it is conceivable that
the role of CEC in anti-angiogenic therapies may be
different.
The source of CEC remains mainly undetermined.
Chang et al [21] suggested a mutual luminal surface of
tumor and endothelial tissue in tumor vessels, which
contribute to the continuous shedding of circulating cells
into the blood stream. Application of therapeutics which
target the tumor vessels is thought to alter the compila-
tion of circulating cells and treatments with angiogenesis
inhibitors were associated with changes of CEC and EPC
in tumor-bearing mice. ZD6126, an inhibitor of VEGFR2,
was associated with a dose-dependent increase of CEC
and decrease of microvessel density, suggesting that inhi-
bition of angiogenesis is associated with gain of CEC
shedding from the tumor vasculature [22].
Currently, the clinical relevance of CEC as a predictive
biomarker for anti-angiogenic therapy has only been
tested in small series and results remain controversial.
In our study, sunitinib treatment was associated with a
significant increase of CEC during the initial 4 weeks of
treatment in patients who achieved a PFS above the
median, whereas patients with a PFS below the median
exhibited no significant increase in CEC. These findings
are supported by other studies, which also determined
significant changes of early biomarkers within 4 weeks
of treatment [4,23]. Prolonged treatment with sunitinib
has been studied in a subgroup of patients with repeated
measures only. In these patients CEC counts decline to
a basal level with sustained sunitinib treatment. There-
fore, we share the notion that the therapy-induced CEC
elevation may represent an early marker for superior
clinical response to sunitinib.
Some limitations are associated in regard to studies
exploring the nature of CEC in patients. Different eva-
luation tools and sampling time points may lead to con-
flicting results. In the phase II study of pazopanib, an
inhibitor of VEGFR1-3, KIT, and PDGFR, evaluation of
biomarkers was included at week 12 [24]. CEC showed
no correlation with tumor response. Our data supports
the notion that CEC may be an early marker, which
must be determined within 4 weeks of therapy initiation
in order to observe biological activity. The mere detec-
tion of CEC counts obviously raises numerous questions
and awaits the development of a more detailed view to
CEC function and vitality, such as analyses of apoptosis
or endothelial cell activation.
We also investigated the potential of circulating
monocytes and sVEGFR2 as putative surrogate markers
to assess sunitinib’s biological activity. Monocytes are
known to express VEGFR1, KIT, and PDGFR and, thus,
may reflect a valuable tool to monitor target inhibition.
Treatment with sunitinib resulted in a marked decrease
of monocyte counts in all patients, which may suggest
adequate target inhibition through sunitinib irrespective
of their clinical response to treatment. As a consequence
of target inhibition, a marked proportional decrease of
monocytes has also been previously reported by other
investigators [4]. In addition, neutrophils and monocytes
have been shown to be elevated in non-responding RCC
patients treated with sunitinib [25]. These studies under-
score the role of monocytes in the process of response
to sunitinib and warrant further studies.
Treatment with sunitinib correlated with increased
VEGF and decreased sVEGFR2 in patient serum, but
correlation with clinical outcome remained mainly
undefined [26-28]. In breast cancer patients, only
decreased sVEGFR3 and sKIT were thought to correlate
with clinical outcome [13]. In RCC patients, no correla-
tion for VEGF, sVEGFR2, sVEGFR3 and efficacy could
be determined [29]. Our results support the notion that
sunitinib-induced target inhibition is associated with
decreased sVEGFR2 concentrations, but the kinetic
modulation of sVEGFR2 levels is insufficient to predict
tumor response throughout the course of therapy.
Our results underline the importance of the incor-
poration of biological markers in anti-angiogenic thera-
pies in order to precisely determine the response to
therapy. The increase of CEC may represent a valuable
tool to predict biological response in RCC patients
undergoing sunitinib treatment, but time of analysis
seems to be crucial in order to detect the clinical rele-
vance of CEC numbers. The small sample size in our
analyses hampers the applicability of our results to the
clinic and requires further careful validation. Clearly,
there is still no single, magic predictive marker for anti-
angiogenic therapy. Rather, a panel of biomarkers has to
be considered in order to obtain a detailed picture of
the effectiveness of the given therapy. Our findings sug-
gest that CEC may be a valuable biomarkers to predict
superior PFS response to sunitinib.
Conclusions
Early increase of circulating endothelial cells is asso-
ciated with superior PFS response to sunitinib and may
serve as an early predictive biomarker. However, mono-
cytes and sVEGFR-2 may exert pharmacodynamic
changes, but fail to correlate with PFS of sunitinib treat-
ment. Further prospective studies are needed to deter-
mine the role of soluble markers in RCC.
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